AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021A Multi-Allelic Molecular-Beacon-Based Real-Time RT-PCR Assay for the Detection of the Coronavirus SARS-CoV-2 from Clinical SamplesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trialView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Usefulness of next-generation sequencing on PBMC samples and HIV-1 DNA quantification in management of treatment optimization in HIV-1 infected virologically suppressed individualsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG+3TC or ATV/r+3TC dual therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Exploration of the possible mechanisms leading to greater mortality in people with limited drug options (LDO)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Determinants of HIV-1 late presentation in patients followed in EuropeView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Exploratory Analysis of Baseline Phenotypic and Genotypic Parameters in Relation to Antiviral Activity for Fostemsavir (FTR) in Heavily Treatment-Experienced (HTE) Patients in the Phase 3 BRIGHTE StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Virological efficacy of switch to 3TC/DTG in a real life cohort of suppressed HIV-1 patients with or without past M184V – The LAMRES StudyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021HIV-1 reverse transcriptase natural polymorphism V106I does not alter the susceptibility and the genetic barrier to resistance to Doravirine in vitro.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Kinetics of archived M184V mutation in HIV-DNA from highly experienced HIV-infected patients with sustained viral suppressionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021Low prevalence of archived M184V/I mutations in 3 HIV-1 suppressed, switch studiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2021HIV-1 subtypes B, G and CRF02_AG transmission cluster in Migrants population followed in Portugal based on sequence dataView Abstract
